Results 131 to 140 of about 1,404,058 (313)
New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond
Therapeutics and Clinical Risk Management, 2011 Bruno Gori1, Serena Ricciardi1, Alberto Fulvi1, Salvatore Intagliata2, Ester Del Signore1, Filippo de Marinis11Oncological-Pulmonary Unit 1st, San Camillo Hospital, Rome, Italy; 2Department of Medical Oncology, University Campus Bio-Medico, Rome ...Gori B, Ricciardi S, Fulvi A, Intagliata S, Del Signore E, de Marinis F +5 moredoaj Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
The Lancet, 2017 A. Rittmeyer, F. Barlesi, D. Waterkamp, Keunchil Park, F. Ciardiello, J. Pawel, S. Gadgeel, T. Hida, D. Kowalski, M. C. Dols, D. Cortinovis, J. Leach, J. Polikoff, C. Barrios, F. Kabbinavar, O. A. Frontera, F. Marinis, H. Turna, Jong-Seok Lee, M. Ballinger, M. Kowanetz, P. He, Daniel S. Chen, A. Sandler, D. Gandara +24 moresemanticscholar +1 more sourceInfrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma
Molecular Oncology, EarlyView.Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn +11 morewiley +1 more sourcePembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
New England Journal of Medicine, 2016 M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, Suman B. Rao, K. Hotta, M. Leiby, G. Lubiniecki, Shentu Yue, Reshma A. Rangwala, J. Brahmer +17 moresemanticscholar +1 more sourceRecurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa +15 morewiley +1 more source2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer [PDF]
, 2017 To complement the existing treatment guidelines, ESMO organises consensus conferences to focus on specific issues. The 2nd ESMO Consensus Conference on Lung Cancer included 35 experts who met to address several questions on non-small-cell lung cancer ...Adjei, Alex, Adjei, Alex, Baas, Paul, Baas, Paul, Besse, Benjamin, Besse, Benjamin, Bubendorf, Lukas, Bubendorf, Lukas, Crinó, Lucio, Crinó, Lucio, De Leyn, P., De Leyn, Paul, De Leyn, Paul, De Ruysscher, D., De Ruysscher, Dirk, De Ruysscher, Dirk, Dooms, Christophe, Dooms, Christophe, Douillard, Jean-Yves, Douillard, Jean-Yves, Eberhardt, W. E. E., Eberhardt, Wilfried, Eberhardt, Wilfried, Edelman, Martin, Edelman, Martin, Faivre-Finn, Corinne, Faivre-Finn, Corinne, Felip, E., Felip, Enriqueta, Felip, Enriqueta, Hoffmann, H., Kerr, Keith, Kerr, Keith, Le Pechoux, Cecile, Le Pechoux, Cecile, Le Péchoux, C., Lim, Eric, Lim, Eric, Marchetti, Antonio, Marchetti, Antonio, Meldgaard, Peter, Meldgaard, Peter, Mok, Tony, Mok, Tony, Nicolson, Marianne, Nicolson, Marianne, Novello, Silvia, Novello, Silvia, O'Byrne, Ken, O'Byrne, Ken, Paz-Ares, Luis, Paz-Ares, Luis, Peters, S., Peters, Solange, Peters, Solange, Reck, Martin, Reck, Martin, Rocco, Gaetano, Rocco, Gaetano, Senan, Suresh, Senan, Suresh, Smit, Egbert F., Smit, Egbert F., Stahel, R., Stahel, Rolf, Stahel, Rolf, Syrigos, Konstantinos, Syrigos, Konstantinos, Van Schil, Paul, Van Schil, Paul, Vansteenkiste, Johan, Vansteenkiste, Johan, Veronesi, Giulia, Veronesi, Giulia, Weder, W., Weder, Walter, Weder, Walter, Westeel, V., Westeel, Virginie, Westeel, Virginie +79 morecore Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
New England Journal of Medicine, 2015 H. Borghaei, L. Paz-Ares, L. Horn, D. Spigel, M. Steins, N. Ready, L. Chow, E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhäufl, O. Arrieta, M. Burgio, J. Fayette, H. Léna, E. Poddubskaya, D. Gerber, S. Gettinger, C. Rudin, N. Rizvi, L. Crinò, G. Blumenschein, S. Antonia, C. Dorange, C. Harbison, Friedrich Graf Finckenstein, J. Brahmer +27 moresemanticscholar +1 more sourcePeroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Molecular Oncology, EarlyView.Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski +17 morewiley +1 more source
